Tango combo clears Rasonque bar, Takeda's Innovent bet gets early returns, plus more from #ESMO26

In a promising development for cancer patients, a large clinical trial has demonstrated that a personalized mRNA cancer vaccine can significantly reduce the likelihood of disease recurrence in patients with melanoma. According to STAT, the vaccine reduced this risk by 42% compared to standard treatment, leading to a marked improvement in patient survival rates.

The experimental vaccine, developed by Merck and Moderna, has generated significant interest as it may pave the way for novel treatments across various cancer types. However, experts are still deliberating the extent to which this technology could be broadly applied to other cancers.

Despite Merck and Moderna announcing the trial's success in August, the full details of the vaccine's effectiveness have been kept under wraps until a presentation at the European Society of Medical Oncology's annual meeting. Fortunately, a news website broke the embargo on Thursday, releasing some of the data ahead of the conference.

The outcome of this trial has sparked a new legal battle involving the Pharmaceutical Research & Manufacturers of America and three drug manufacturers. A U.S. judge has granted their request to join a lawsuit over a government rebate pilot program, set to commence on January 1. Hospitals have challenged the U.S. Health Resources & Services Administration's decision to allow drugmakers to provide rebates instead of upfront discounts for medicines purchased through the 340B Drug Discount Program.

The court's ruling will allow the trade group, AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim to participate in the legal proceedings.